Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab and Balstilimab in First-Line Metastatic Non-Small Cell Lung Cancer
NCT06322108Phase 2Active, not recruiting
- Sponsor
- Immune Oncology Research Institute
- Start
- Jun 2024
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in non-small cell lung cancer (NSCLC), sponsored by Immune Oncology Research Institute. Started Jun 2024; status: active, not recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06322108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06322108.